USPTO serial 79397608
VALINK THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 15, 2025
- Examiner
- SPILS, CAROL A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VALINK THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
US
US
US
US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew A. Homyk
Matthew A. Homyk Blank Rome LLPOne Logan SquarePhiladelphia, PA 19103United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; biological preparations for use in industry and science; proteins for use in science; proteins for use in industry; proteins for detecting antibodies, other than for medical use; proteins for binding antibodies, other than for medical use; immunological antibodies, other than for medical use; chemical substances for use in the biotechnological industry; chemicals for use in the pharmaceutical industry; chemical substances for use in the production of drugs; chemicals for use in scientific research, other than medical or veterinary; chemicals for use in biotechnological product development | ACTIVE | — |
| 005 | Pharmaceuticals, medical and veterinary preparations for the prevention and treatment of cancer in humans and animals; pharmaceutical drugs for the prevention and treatment of cancer in humans and animals; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; anti-cancer drugs; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of tumours; chemotherapeutics; biotechnological preparations for medical use for the treatment of cancer; antibodies for medical purposes | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto in the fields of pharmaceutical, biomedical, and chemical sciences; biotechnology research; biological research; clinical research in the field of radiology and chemotherapy; medical research; scientific research for medical purposes; research and development of vaccines and medicines; scientific research for medical purposes in the area of cancerous diseases; research and development services in the field of antibodies; research and development in the pharmaceutical and biotechnology fields; biotechnology testing; scientific research relating to biotechnology; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research and development for the pharmaceutical industry; conducting clinical trials for pharmaceutical products; testing of pharmaceuticals; biochemical research services of biochemistry drugs; biochemistry consultancy; biochemistry research services; biochemical research and development; research and development in the field of biotechnology; biochemical engineering services; scientific laboratory services; biochemical research laboratory services; medical research laboratory services; medical research laboratories; providing information relating to scientific research in the fields of biochemistry and biotechnology; consultancy in the field of pharmaceutical research; scientific consultancy in the field of biotechnology; consultancy relating to research and development in the field of therapeutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Valink Therapeutics Inc.
- Other trademarks owned by Valink Therapeutics Inc.
- Other trademarks owned by Valink Therapeutics Inc.
- Other trademarks owned by Valink Therapeutics Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named VALINK THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 30, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 22, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 5, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 4, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 16, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 4, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 16, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 15, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 15, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 25, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 19, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 4, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 4, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 4, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 4, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 13, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 13, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 13, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 13, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 13, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 17, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 15, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 10, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |